Trials / Completed
CompletedNCT03772613
The Randomized OPTIMAL-ACT Trial
Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Unfractionated heparin | Administration of unfractionated heparin will be assessed using the activated clotting time |
Timeline
- Start date
- 2019-02-08
- Primary completion
- 2021-10-25
- Completion
- 2021-10-25
- First posted
- 2018-12-11
- Last updated
- 2023-04-04
- Results posted
- 2023-04-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03772613. Inclusion in this directory is not an endorsement.